Reduced thymic expression of ErbB receptors without auto-antibodies against synaptic ErbB in myasthenia gravis

Journal of Neuroimmunology

Volumn 232, Issue 1-2, 2011, Pages 158-165

  Vrolix, Kathleen ^a   Niks, Erik H ^b   Le Panse, Rozen ^c   van Ostaijen ten Dam, Monique M ^b   Muris, Anne Hilde ^a   Jol van der Zijde, Cornelia M ^b   van Tol, Maarten J D ^b   Losen, Mario ^a   Molenaar, Peter C ^a   van Zoelen, Everardus J J ^d   Berrih Aknin, Sonia ^c   De Baets, Marc H ^a,e   Verschuuren, Jan J G M ^b   Martínez Martínez, Pilar ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c INSERM   (France)

^d RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^e HASSELT UNIVERSITY   (Belgium)

Author keywords

Auto antibodies; ErbB; Myasthenia gravis; Neuromuscular junction

Indexed keywords

AUTOANTIBODY; CHOLINERGIC RECEPTOR; CHOLINESTERASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; IMMUNOSUPPRESSIVE AGENT; MESSENGER RNA;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; GENE SEQUENCE; HUMAN; HUMAN TISSUE; MYASTHENIA GRAVIS; NERVE STIMULATION; NEUROMUSCULAR SYNAPSE; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; THYMUS; TISSUE MICROARRAY;

ADOLESCENT; ADULT; AGED; AUTOANTIBODIES; AUTOANTIGENS; CELL SEPARATION; CHILD; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOBLOTTING; MALE; MICROARRAY ANALYSIS; MIDDLE AGED; MYASTHENIA GRAVIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, MESSENGER; SYNAPSES; THYMUS GLAND; YOUNG ADULT;

EID: 79951823855     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2010.10.024     Document Type: Article

References (50)

1. Aharonov A., Tarrab-Hazdai R., Abramsky O., Fuchs S. Immunological relationship between acetylcholine receptor and thymus: a possible significance in myasthenia gravis. Proc Natl Acad Sci USA 1975, 72:1456-1459.
2. Baselga J., Tripathy D., Mendelsohn J., Baughman S., Benz C.C., Dantis L., Sklarin N.T., Seidman A.D., Hudis C.A., Moore J., Rosen P.P., Twaddell T., Henderson I.C., Norton L. Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. Semin Oncol 1999, 26:78-83.
3. Buonanno A., Fischbach G.D. Neuregulin and ErbB receptor signaling pathways in the nervous system. Curr Opin Neurobiol 2001, 11:287-296.
4. Burke G., Cossins J., Maxwell S., Owens G., Vincent A., Robb S., Nicolle M., Hilton-Jones D., Newsom-Davis J., Palace J., Beeson D. Rapsyn mutations in hereditary myasthenia: distinct early- and late-onset phenotypes. Neurology 2003, 61:826-828.
5. Chan K.H., Lachance D.H., Harper C.M., Lennon V.A. Frequency of seronegativity in adult-acquired generalized myasthenia gravis. Muscle Nerve 2007, 36:651-658.
6. Cizeron-Clairac G., Le Panse R., Frenkian-Cuvelier M., Meraouna A., Truffault F., Bismuth J., Mussot S., Kerlero de Rosbo N., Berrih-Aknin S. Thymus and Myasthenia Gravis: what can we learn from DNA microarrays?. J Neuroimmunol 2008, 201-202:57-63.
7. Cobleigh M.A., Vogel C.L., Tripathy D., Robert N.J., Scholl S., Fehrenbacher L., Wolter J.M., Paton V., Shak S., Lieberman G., Slamon D.J. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999, 17:2639-2648.
8. Conti-Fine B.M., Milani M., Kaminski H.J. Myasthenia gravis: past, present, and future. J Clin Invest 2006, 116:2843-2854.
9. Drachman D.B. Myasthenia gravis. N Engl J Med 1994, 330:1797-1810.
10. Engel A.G., Tsujihata M., Lindstrom J.M., Lennon V.A. The motor end plate in myasthenia gravis and in experimental autoimmune myasthenia gravis. A quantitative ultrastructural study. Ann NY Acad Sci 1976, 274:60-79.
11. Engel A.G., Lindstrom J.M., Lambert E.H., Lennon V.A. Ultrastructural localization of the acetylcholine receptor in myasthenia gravis and in its experimental autoimmune model. Neurology 1977, 27:307-315.
12. Evoli A., Tonali P.A., Padua L., Monaco M.L., Scuderi F., Batocchi A.P., Marino M., Bartoccioni E. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain 2003, 126:2304-2311.
13. Giraud M., Taubert R., Vandiedonck C., Ke X., Levi-Strauss M., Pagani F., Baralle F.E., Eymard B., Tranchant C., Gajdos P., Vincent A., Willcox N., Beeson D., Kyewski B., Garchon H.J. An IRF8-binding promoter variant and AIRE control CHRNA1 promiscuous expression in thymus. Nature 2007, 448:934-937.
14. Gronseth G.S., Barohn R.J. Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000, 55:7-15.
15. Guyon T., Wakkach A., Poea S., Mouly V., Klingel-Schmitt I., Levasseur P., Beeson D., Asher O., Tzartos S., Berrih-Aknin S. Regulation of acetylcholine receptor gene expression in human myasthenia gravis muscles. Evidences for a compensatory mechanism triggered by receptor loss. J Clin Invest 1998, 102:249-263.
16. Hoch W., McConville J., Helms S., Newsom-Davis J., Melms A., Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 2001, 7:365-368.
17. Jaretzki A., Barohn R.J., Ernstoff R.M., Kaminski H.J., Keesey J.C., Penn A.S., Sanders D.B. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Ann Thorac Surg 2000, 70:327-334.
18. Jo S.A., Zhu X., Marchionni M.A., Burden S.J. Neuregulins are concentrated at nerve-muscle synapses and activate ACh-receptor gene expression. Nature 1995, 373:158-161.
19. Kamo I., Furukawa S., Tada A., Mano Y., Iwasaki Y., Furuse T., Ito N., Hayashi K., Satoyoshi E. Monoclonal antibody to acetylcholine receptor: cell line established from thymus of patient with Myasthenia gravis. Science 1982, 215:995-997.
20. Kuks J.B., Oosterhuis H.J., Limburg P.C., The T.H. Anti-acetylcholine receptor antibodies decrease after thymectomy in patients with myasthenia gravis. Clinical correlations. J Autoimmun 1991, 4:197-211.
21. Kummer T.T., Misgeld T., Sanes J.R. Assembly of the postsynaptic membrane at the neuromuscular junction: paradigm lost. Curr Opin Neurobiol 2006, 16:74-82.
22. Lauriola L., Ranelletti F., Maggiano N., Guerriero M., Punzi C., Marsili F., Bartoccioni E., Evoli A. Thymus changes in anti-MuSK-positive and -negative myasthenia gravis. Neurology 2005, 64:536-538.
23. Le Panse R., Cizeron-Clairac G., Bismuth J., Berrih-Aknin S. Microarrays reveal distinct gene signatures in the thymus of seropositive and seronegative myasthenia gravis patients and the role of CC chemokine ligand 21 in thymic hyperplasia. J Immunol 2006, 177:7868-7879.
24. Leite M.I., Strobel P., Jones M., Micklem K., Moritz R., Gold R., Niks E.H., Berrih-Aknin S., Scaravilli F., Canelhas A., Marx A., Newsom-Davis J., Willcox N., Vincent A. Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG. Ann Neurol 2005, 57:444-448.
25. Leite M.I., Jones M., Strobel P., Marx A., Gold R., Niks E., Verschuuren J.J., Berrih-Aknin S., Scaravilli F., Canelhas A., Morgan B.P., Vincent A., Willcox N. Myasthenia gravis thymus: complement vulnerability of epithelial and myoid cells, complement attack on them, and correlations with autoantibody status. Am J Pathol 2007, 171:893-905.
26. Leite M.I., Jacob S., Viegas S., Cossins J., Clover L., Morgan B.P., Beeson D., Willcox N., Vincent A. IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis. Brain 2008, 131:1940-1952.
27. Lemke G. Neuregulins in development. Mol Cell Neurosci 1996, 7:247-262.
28. Levinson A.I., Wheatley L.M. The thymus and the pathogenesis of myasthenia gravis. Clin Immunol Immunopathol 1996, 78:1-5.
29. Lindstrom J.M., Seybold M.E., Lennon V.A., Whittingham S., Duane D.D. Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology 1976, 26:1054-1059.
30. Liston A., Lesage S., Gray D.H., Boyd R.L., Goodnow C.C. Genetic lesions in T-cell tolerance and thresholds for autoimmunity. Immunol Rev 2005, 204:87-101.
31. Melms A., Schalke B.C., Kirchner T., Muller-Hermelink H.K., Albert E., Wekerle H. Thymus in myasthenia gravis. Isolation of T-lymphocyte lines specific for the nicotinic acetylcholine receptor from thymuses of myasthenic patients. J Clin Invest 1988, 81:902-908.
32. Mencarelli C., Hammels C., Van Den Broeck J., Losen M., Steinbusch H., Revert F., Saus J., Hopkins D.A., De Baets M.H., Steinbusch H.W., Martinez-Martinez P. The expression of the Goodpasture antigen-binding protein (ceramide transporter) in adult rat brain. J Chem Neuroanat 2009, 38(2):97-105.
33. Muppidi S., Wolfe G.I. Muscle-specific receptor tyrosine kinase antibody-positive and seronegative myasthenia gravis. Front Neurol Neurosci 2009, 26:109-119.
34. Niks E.H., Kuks J.B., Verschuuren J.J. Epidemiology of myasthenia gravis with anti-muscle specific kinase antibodies in The Netherlands. J Neurol Neurosurg Psychiatry 2007, 78:417-418.
35. Pugliese A., Zeller M., Fernandez A., Zalcberg L.J., Bartlett R.J., Ricordi C., Pietropaolo M., Eisenbarth G.S., Bennett S.T., Patel D.D. The insulin gene is transcribed in the human thymus and transcription levels correlated with allelic variation at the INS VNTR-IDDM2 susceptibility locus for type 1 diabetes. Nat Genet 1997, 15:293-297.
36. Rimer M. Neuregulins: primary or secondary signals for the control of synapse-specific gene expression. J Neurocytol 2003, 32:665-675.
37. Ross J.S., Slodkowska E.A., Symmans W.F., Pusztai L., Ravdin P.M., Hortobagyi G.N. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 2009, 14:320-368.
38. Salmon A.M., Bruand C., Cardona A., Changeux J.P., Berrih-Aknin S. An acetylcholine receptor alpha subunit promoter confers intrathymic expression in transgenic mice. Implications for tolerance of a transgenic self-antigen and for autoreactivity in myasthenia gravis. J Clin Invest 1998, 101:2340-2350.
39. Sandrock A.W., Dryer S.E., Rosen K.M., Gozani S.N., Kramer R., Theill L.E., Fischbach G.D. Maintenance of acetylcholine receptor number by neuregulins at the neuromuscular junction in vivo. Science 1997, 276:599-603.
40. Sanes J.R., Lichtman J.W. Development of the vertebrate neuromuscular junction. Annu Rev Neurosci 1999, 22:389-442.
41. Sims G.P., Shiono H., Willcox N., Stott D.I. Somatic hypermutation and selection of B cells in thymic germinal centers responding to acetylcholine receptor in myasthenia gravis. J Immunol 2001, 167:1935-1944.
42. Toyka K.V., Brachman D.B., Pestronk A., Kao I. Myasthenia gravis: passive transfer from man to mouse. Science 1975, 190:397-399.
43. Trinidad J.C., Fischbach G.D., Cohen J.B. The Agrin/MuSK signaling pathway is spatially segregated from the neuregulin/ErbB receptor signaling pathway at the neuromuscular junction. J Neurosci 2000, 20:8762-8770.
44. Vincent A. Unravelling the pathogenesis of myasthenia gravis. Nat Rev Immunol 2002, 2:797-804.
45. Vincent A., Scadding G.K., Thomas H.C., Newsom-Davis J. In-vitro synthesis of anti-acetylcholine-receptor antibody by thymic lymphocytes in myasthenia gravis. Lancet 1978, 1:305-307.
46. Wakkach A., Guyon T., Bruand C., Tzartos S., Cohen-Kaminsky S., Berrih-Aknin S. Expression of acetylcholine receptor genes in human thymic epithelial cells: implications for myasthenia gravis. J Immunol 1996, 157:3752-3760.
47. Wekerle H., Ketelsen U.P., Zurn A.D., Fulpius B.W. Intrathymic pathogenesis of myasthenia gravis: transient expression of acetylcholine receptors on thymus-derived myogenic cells. Eur J Immunol 1978, 8:579-582.
48. Zhang, W.J., Leite, M.I., Vincent, A., Cox, A.L., 2010. Autoantibodies in 'seronegative' myasthenia gravis. J Neurol Neurosurg Psychiatry 81 (11), e25.
49. Zhou L., McConville J., Chaudhry V., Adams R.N., Skolasky R.L., Vincent A., Drachman D.B. Clinical comparison of muscle-specific tyrosine kinase (MuSK) antibody-positive and -negative myasthenic patients. Muscle Nerve 2004, 30:55-60.
50. Zhu X., Lai C., Thomas S., Burden S.J. Neuregulin receptors, erbB3 and erbB4, are localized at neuromuscular synapses. EMBO J 1995, 14:5842-5848.